This is in line with a previous study on ovarian cancer [8], wherein RBM3 levels were found to be significantly higher in parental A2780 ovarian cancer cells compared to their cisplatin-resistant derivative, and reduced cisplatin-sensitivity upon RBM3 knockdown in the former. This evidence concerns the gene RBM3 and ovarian carcinoma.